Compound Radar

Guardant Health, Inc. (GH) Stock Analysis

Price $160.98
Market cap $21.60B
Next earnings Oct 28, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 30
  • Profitability 70
  • Business Quality 75
  • Balance Sheet 30
  • Cash Flow 25

Why this rating?

Health 45/100 — Speculative

Strongest Business Quality 75/100
Softest Cash Flow 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Guardant Health, Inc. (GH) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Guardant Health, Inc. 45/100 (Speculative) due to high business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality High
  • Growth Strong
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -363.92
  • EV/Revenue 18.85

Profitability

  • Revenue Growth 44.3%
  • Gross Margin 65.0%
  • Operating Margin -38.2%
  • Net Margin -38.3%

Financial strength

  • Cash $1.05B
  • Debt $1.70B
  • Net Cash $-643.54M
  • Free Cash Flow $-233.07M
  • Current Ratio 4.03

Similar companies

Peers in Diagnostics & Research, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Diagnostics & Research →

FAQ

How Compound Radar scores and tracks Guardant Health, Inc. (GH).

View Methodology & FAQ →